

29 January 2024

Vale Lang Walker AO

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today pays tribute to longstanding supporter of the Company, Lang Walker AO, who passed away on Saturday, 27 January 2024.¹

Next Science’s Chair Aileen Stockburger said: “It is with deep sadness that the Board has learned of the passing of Mr Walker who has been a dedicated advocate of Next Science and its unique X-BIO™ technology. We are grateful for the important contribution he made to our Company and offer our sincere condolences to Mr Walker’s family and friends.”

Mr Walker holds a related party interest in the Company of around 37%² via Walker Group Holdings Pty Limited and Auckland Trust Company Limited.

Approved and authorised for release by the Board of Directors.

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company’s primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

¹ [Vale Lang Alexander Walker AO, Walker Group](#)

² Refer to *Change in Substantial Shareholding Notice* lodged on ASX on 1 November 2023.